KIT Signaling Promotes Growth of Colon Xenograft Tumors in Mice and Is Up-Regulated in a Subset of Human Colon Cancers
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background & Aims Receptor tyrosine kinase (RTK) inhibitors have advanced colon cancer treatment. We investigated the role of the RTK KIT in development of human colon cancer. Methods An array of 137 patient-derived colon tumors and their associated xenografts were analyzed by immunohistochemistry to measure levels of KIT and its ligand KITLG. KIT and/or KITLG was stably knocked down by expression of small hairpin RNAs from lentiviral vectors in DLD1, HT29, LS174T, and COLO320 colon cancer cell lines, and in UM-COLON#8 and POP77 xenografts; cells transduced with only vector were used as controls. Cells were analyzed by real-time quantitative reverse transcription PCR, single-cell gene expression analysis, flow cytometry, and immunohistochemical, immunoblot, and functional assays. Xenograft tumors were grown from control and KIT-knockdown DLD1 and UM-COLON#8 cells in immunocompromised mice and compared. Some mice were given the RTK inhibitor imatinib following injection of cancer cells; tumor growth was measured based on bioluminescence. We assessed tumorigenicity using limiting dilution analysis. Results KIT and KITLG were expressed heterogeneously by a subset of human colon tumors. Knockdown of KIT decreased proliferation of colon cancer cell lines and growth of xenograft tumors in mice, compared with control cells. KIT knockdown cells had increased expression of enterocyte markers, decreased expression of cycling genes, and, unexpectedly, increased expression of LGR5-associated genes. No activating mutations in KIT were detected in DLD1, POP77, or UM-COLON#8 cell lines. However, KITLG-knockdown DLD1 cells formed smaller xenograft tumors than control cells. Gene expression analysis of single CD44+ cells indicated that KIT may promote growth via KITLG autocrine and/or paracrine signaling. Imatinib inhibited growth of KIT+ colon cancer organoids in culture and growth of xenograft tumors in mice. Cancer cells with endogenous KIT expression were more tumorigenic in mice. Conclusions KIT and KITLG are expressed by a subset of human colon tumors. KIT signaling promotes growth of colon cancer cells and organoids in culture and xenograft tumors in mice via its ligand, KITLG, in an autocrine or paracrine manner. Patients with KIT-expressing colon tumors may benefit from KIT RTK inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Proteogenomic characterization of human colon and rectal cancer
CPTAC, T. N., Zhang, B., Wang, J., Wang, X., Zhu, J., Liu, Q., Shi, Z., Chambers, M. C., Zimmerman, L. J., Shaddox, K. F., et al. (2014) · Nature · doi:10.1038/nature13438 · Cited by 1,462
Merlos-Suárez, A., Barriga, F. M., Jung, P., Iglesias, M., Céspedes, M. V., Rossell, D., Sevillano, M., Hernando-Momblona, X., da Silva-Diz, V., Muñoz, P., et al. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.02.020 · Cited by 934
Intestinal label-retaining cells are secretory precursors expressing Lgr5
Buczacki, S. J. A., Zecchini, H. I., Nicholson, A. M., Russell, R., Vermeulen, L., Kemp, R., & Winton, D. J. (2013) · Nature · doi:10.1038/nature11965 · Cited by 761
Melanoma: from mutations to medicine
Tsao, H., Chin, L., Garraway, L. A., & Fisher, D. E. (2012) · Genes & Development · doi:10.1101/gad.191999.112 · Cited by 496
Rothenberg, M. E., Nusse, Y., Kalisky, T., Lee, J. J., Dalerba, P., Scheeren, F., Lobo, N., Kulkarni, S., Sim, S., Qian, D., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.006 · Cited by 263
Self-citation
Cited by
Clinical and Therapeutic Implications of Cancer Stem Cells
Clarke, M. F. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1804280 · Cited by 355
Self-citationMolecular Insight of Regorafenib Treatment for Colorectal Cancer
Arai, H., Battaglin, F., Wang, J., Lo, J. H., Soni, S., Zhang, W., & Lenz, H.-J. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101912 · Cited by 191
“Their findings could propose the hypothesis that a subset of CRC patients expressing c-KIT may benefit from c-KIT inhibiting drugs such as regorafenib and imatinib, but clinical evidence is lacked so far [69,70].”
BackgroundUbink, I., Elias, S. G., Moelans, C. B., Laclé, M. M., van Grevenstein, W. M. U., van Diest, P. J., Borel Rinkes, I. H. M., & Kranenburg, O. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djw303 · Cited by 40
Peters, N. A., Constantinides, A., Ubink, I., van Kuik, J., Bloemendal, H. J., van Dodewaard, J. M., Brink, M. A., Schwartz, T. P., Lolkema, M. P. J. K., Lacle, M. M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.969855 · Cited by 35
“Imatinib was selected as a CMS4-targeting drug, based on the very high expression of its targets in CMS4 (this study), its anti-metastatic activity in various pre-clinical models (8, 11, 21), and the potential for rapid future clinical development (22, 23).”
BackgroundKüçükköse, E., Peters, N. A., Ubink, I., van Keulen, V. A. M., Daghighian, R., Verheem, A., Laoukili, J., & Kranenburg, O. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05078-z · Cited by 18
“However, we and others have previously shown that signaling by (wild-type) KIT maintains stem-like cancer cells in CRC and is required for colony- and tumor-forming potential [17, 18].”
Background
Metadata
- Authors
- Chen, E. C., Karl, T. A., Kalisky, T., Gupta, S. K., O’Brien, C. A., Longacre, T. A., van de Rijn, M., Quake, S. R., Clarke, M. F., & Rothenberg, M. E.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 149
- Issue
- 3
- Pages
- 705-717.e2
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2161654775
- Cited by
- 43
- References
- 6
- FWCI
- 1.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: KIT Signaling Promotes Growth of Colon Xenograft Tumors in Mice and Is Up-Regulated in a Subset of Human Colon Cancers. https://app.cochat.ai/papers/10.1053/j.gastro.2015.05.042
- The paper
- Chen, E. C., Karl, T. A., Kalisky, T., Gupta, S. K., O’Brien, C. A., Longacre, T. A., van de Rijn, M., Quake, S. R., Clarke, M. F., & Rothenberg, M. E. (2015). KIT Signaling Promotes Growth of Colon Xenograft Tumors in Mice and Is Up-Regulated in a Subset of Human Colon Cancers. Gastroenterology. https://doi.org/10.1053/j.gastro.2015.05.042
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.